Boyds bolsters clinical operations team as demand for clinical trial expertise and support surges
We are delighted to announce the appointment of experienced clinical researcher Caroline Corbett as Director of Clinical Operations to support the team’s continued growth and the rising demand for its specialist clinical trial expertise. As Director of Clinical Operations at Boyds, Caroline will support Dr Karen O’Hanlon, Vice President of Clinical Operations, with the ongoing […]
Dr Karen Mullen appointed as Chief Medical Officer
Boyds is delighted to announce the appointment of experienced pharmaceutical physician Dr Karen Mullen FFPM as Chief Medical Offer (CMO) and Vice President of Clinical and Medical Affairs. Karen joins Boyds from GlaxoSmithKline, with her most recent role being Country Medical Director for the UK and Ireland in which she led and managed a large […]
Strong growth in the US boosts revenue for Boyds
Boyds is delighted to report another strong year of growth, with an increase in excess of 20 percent year-on-year in annual revenue in the wake of increased demand for our specialist expertise across the UK, US, and Europe. Since the opening of our US office in Pennsylvania last year, headed by Katy Rudnick, we have […]
Boyds boosts specialist clinical expertise with appointment of Dr Harriet Gray Stephens
Boyds is delighted to announce the appointment of Pharmaceutical Physician, Dr Harriet Gray Stephens, to the Clinical and Medical Affairs group to further strengthen the companies clinical expertise. Harriet joins Boyds from GlaxoSmithKline’s Clinical Research Unit in Cambridge where she was a Clinical Research Physician. After qualifying in Medicine at the University of Oxford, and […]
Katy Rudnick awarded Aiko Maruya award for Excellence in Regulatory Science
Boyds congratulates Katy Rudnick, Vice President and Head of US Regulatory Affairs, on being awarded the Aiko Maruya Award from the USC School of Pharmacy. Katy is currently enrolled on the regulatory doctorate program at University of Southern California where she is working on her dissertation. The USC DRSc program is the only doctoral program […]
Pippa Bjaaland graduates with MSc in Cancer and Clinical Oncology with distinction.
Boyds is delighted to congratulate Pippa Bjaaland, Senior CRA at Boyds, on graduating with an MSc in Cancer and Clinical Oncology from Queen Mary University of London. Pippa completed the part-time 2-year course in October 2021 and recently attended her graduation ceremony to celebrate the achievement. Pippa completed her part-time MSc in Cancer and Clinical […]
Eamonn McGowran: Medical Devices Regulatory Specialist joins Boyds
Boyds is delighted to announce the appointment of regulatory expert in the pharma, biotech and medical devices sectors, Eamonn McGowran, as Associate Director. Based at Boyds’ Irish operation at Talent Garden Dublin, Eamonn’s appointment marks the beginning of the next phase of growth and expansion in Dublin and Europe for Boyds, which will harness his […]
Boyds goes for growth with key appointment of Dr Neil Fish
Boyds is delighted to announce the appointment of business development expert Dr Neil Fish to support the company as it embarks on the next stage of its global expansion. With over 35 years’ experience in the life sciences industry and an outstanding track record of completing deals, Neil joins the Boyds team as Vice President […]
Boyds expands product development team
Boyds has added two experienced product development experts to its team, amid growing demand for specialist Product Development services from clients in the UK, Europe and the US. Diane Shattock Ph.D., joins as Director of Product Development and Ian Hollingsworth M.Sc., as Associate Director of Product Development. Both are working alongside Boyds’ Vice President of Product Development, […]
Boyds shortlisted in 2021 TOPRA Awards
Two of Boyds’ regulatory team members have been shortlisted in the TOPRA Awards for Regulatory Excellence. Sabine Ruehle, Senior Manager of Regulatory Affairs, is a finalist in the ‘Support’ category, a nomination made jointly with the AstraZeneca team with whom she worked closely on the environmental risk assessment for its COVID-19 vaccine. Victoria Marsh, Director […]
